Quanterix Corp
NASDAQ:QTRX
Quanterix Corp
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
Revenue: Q4 revenue was $43.9 million, up 25% year-over-year and up 7% sequentially, driven by better-than-expected academic demand.
Profitability: Company expects cash flow breakeven in the second half of 2026 and to end the year with approximately $100 million of cash and no debt.
Guidance: 2026 revenue guide of $169 million to $174 million, which implies roughly a 2% pro forma increase at the midpoint after excluding a terminated diagnostics agreement.
Diagnostics progress: Lucent AD complete secured a CMS reimbursement crosswalk of $897, a 510(k) was submitted in January 2026, and management expects FDA review in ~6–9 months.
Cost actions: $74 million of $85 million cost synergy target implemented; operating discipline helped adjusted cash usage improve to $3 million in Q4 from $16.1 million in Q3.
Products & pipeline: Launched 13 assays in 2025, early access for Simoa ONE is underway and the company plans a steady cadence of assay launches through 2026.
